+)水平[SMD=1.25,95% CI=(1.04,1.46)]、表面抗原分化簇4(CD4+)水平[SMD=1.25,95% CI=(0.88,1.95)]、表面抗原分化簇8(CD8+)水平[SMD=-1.68,95% CI=(-1.92,-1.44)],CD4+/CD8+[SMD=1.10,95% CI=(0.86,1.34)],且差異均有統(tǒng)計學意義(P<0.01)。結論 參芪扶正注射液輔助化療可以改善免疫功能,降低相關指標水平,綜合提高晚期胃癌患者的近期療效,但相關研究較少,化療方案不統(tǒng)一,各研究納入的患者數量相對較少,相關指標存在一定的異質性,對患者生存時間的評估仍需要更深入的臨床研究。;Objective To evaluate the efficacy of Shenqi Fuzheng Injection as adjuvant chemotherapy in patients with advanced gastric cancer and its effect on immune function. Methods Chinese and English databases were searched, including CNKI, CBM, VIP, Wanfang, Cochrane Library, PubMed, Embase, etc., from the establishment of the database to June 2021. Screening the clinical controlled trial of shenqi Fuzheng injection in the adjuvant treatment of advanced gastric cancer. Meta-analysis was performed on the included studies using RevMan 5.3 software. Results A total of 662 patients were included in 8 studies. Meta-analysis showed that compared with the control group, Shenqi Fuzheng Injection assisted chemotherapy could improve the clinical efficacy[RR=1.36, 95%CI=(1.22, 1.51)]; increased the level of CD3+[SMD=1.25, 95%CI=(1.04, 1.46)], CD4+[SMD=1.25, 95%CI=(0.88, 1.95)], CD8+[SMD=-1.68, 95%CI=(-1.92, -1.44)], CD4+/CD8+[SMD=1.10, 95%CI=(0.86, 1.34)], and the differences were statistically significant (P<0.01). Conclusion Shenqi Fuzheng Injection adjuvant chemotherapy can improve the immune function, lower levels of related indicators, comprehensive improve the recent curative effect of patients with advanced gastric cancer, but the related research is less, chemotherapy regimens are not unified, the research into the relatively small number of patients, the index has certain heterogeneity, survival time of patients of evaluation still needs further clinical research."/>

久久久久亚洲精品,久久无码av三级,娇妻借朋友高h繁交h,久久男人av资源站,狠狠久久五月精品中文字幕

首頁 > 過刊瀏覽>2021年第44卷第10期 >2021,44(10):2225-2233. DOI:10.7501/j.issn.1674-6376.2021.10.025
上一篇 | 下一篇

參芪扶正注射液聯(lián)合化療對晚期胃癌有效性及免疫功能影響的Meta分析

Shenqi Fuzheng Injection adjuvant chemotherapy on effectiveness and immune function of advanced gastric cancer: A Meta-analysis

發(fā)布日期:2021-10-08
您是第位訪問者
藥物評價研究 ® 2025 版權所有
技術支持:北京勤云科技發(fā)展有限公司
津備案:津ICP備13000267號 互聯(lián)網藥品信息服務資格證書編號:(津)-非經營性-2015-0031